Implied Podcast
Season 1
by Implied Podcast™
Robinhood just became the S&P 500’s biggest loser, sliding nearly 10% in a single day as Bitcoin’s weekend crash dragged the brokerage down with it. With crypto now fueling a massive 41% of their transaction revenue, the platform has evolved into a high-stakes crypto proxy—leaving investors to wonder if it’s still a "stock" app at all. In this episode, we peel back the curtain on the chaos: from Cathie Wood’s Ark Invest buying the dip to the "oversold" technical signals flashing green. But with insiders dumping millions in shares and the shadow of a "crypto winter" looming, is this a rare discount on a future financial giant or a warning sign to stay away? Tune in to find out why Robinhood is currently a hostage to Bitcoin’s volatility.
Unity Software just took a brutal 12% nosedive after Google unveiled Project Genie—a generative AI powerhouse that can "prompt" entire interactive worlds into existence. Is this the end of traditional game development as we know it, or just a massive overreaction from a panicked market? In this episode of Implied, we peel back the curtain on Unity’s identity crisis. While executives have quietly dumped $75 million in stock over the last 90 days, heavy hitters at Goldman Sachs and Wells Fargo are actually raising their price targets. We break down the "AI-ification" of gaming, the CEO's defiant defense, and whether Unity’s upcoming earnings call on February 11th will be a redemption story or a final reality check.
Joby Aviation just sent shockwaves through the eVTOL sector, cratering 16% in a single day and wiping out months of momentum. The "moonshot" phase has officially met a cold reality check following a missed FAA milestone and a sudden cooling of the Toyota partnership hype. With reports of a year-long delay to their commercial launch and eyebrow-raising insider selling, investors are asking: is this a temporary turbulence or a total system failure? In this episode of Implied, we break down the FAA hurdles, the "sympathy drop" hitting competitors like Archer, and why Joby’s massive cash pile might be the only thing keeping this crash from becoming a catastrophe. Tune in to find out if this 16% dip is a painful reset or a warning to stay on the ground.
Carvana just hit a massive speed bump, crashing 20% in a single day after a scathing report from Gotham City Research. The allegations are explosive: a $1 billion hole in the books and claims that Carvana’s "record profits" are actually a mirage propped up by secret, "incestuous" deals with the CEO’s family businesses. In this episode of Implied, we dig into the claims of artificial gains, the 40x debt-to-earnings ratio looming over their partners, and whether Carvana is a logistics marvel or a financial thriller waiting for a crash. Is this the ultimate buying opportunity, or is the "family business" finally catching up to them? Tune in to go behind the numbers.
Figma just hit a painful milestone: its stock is hovering around $29, officially sliding below its $33 IPO price. Despite crossing the massive $1 billion annual recurring revenue mark with elite 90% gross margins, Wall Street is hit with a "post-IPO hangover." In this episode, we dive into why the market is panicking over a $1 billion GAAP loss fueled by one-time stock comps while ignoring Figma’s $1.6 billion cash pile and zero debt. Is this a "baby with the bathwater" situation caused by lockup expirations, or is Adobe’s AI counter-offensive finally catching up? Tune in to find out if Figma is a high-quality business trapped in a low-quality chart.
Revolution Medicines (RVMD) just saw its stock crater 17% after reports surfaced that Merck has officially pulled the plug on its rumored $30 billion takeover. After weeks of intense M&A hype and a 50% rally, the "takeover premium" is evaporating, leaving investors with a classic case of "selling the lack of news." In this episode, we break down: • The Valuation Standoff: Why Merck walked away from the table and why AbbVie isn't coming to the rescue. • The "Zero Revenue" Reality: How a company burning $1 billion a year maintains a massive $1.9 billion cash cushion. • The Science vs. The Hype: Why the upcoming Phase 3 data for daraxonrasib might be the only thing that can save the bulls. Is this a crash to avoid, or a rare, discounted entry into the "holy grail" of oncology? Tune in to find out if the science under the hood is enough to overcome the loss of a mega-merger.
Legend Biotech just slammed into a new 52-week low, plunging 11% after missing sales estimates for its flagship cancer drug, Carvykti. Wall Street’s reaction was brutal—with analysts slashing price targets from $62 to $21—but management is standing firm on its $3 billion forecast. Is this a disastrous sign of stalling demand, or does the crash make Legend a bargain buyout target for Big Pharma? In this episode, we break down the numbers to see if this is a value trap or a golden opportunity in the cell therapy space.
AeroVironment (AVAV) just shed nearly 16% after the U.S. government slammed the brakes with a surprise "Stop Work Order" on its classified BADGER program. Despite explosive 151% revenue growth from the recent BlueHalo acquisition, a messy earnings miss and this sudden Pentagon freeze have investors running for the exits. Is this a sign of deep trouble in their defense contracts, or is the market ignoring a $1.4 billion backlog and a rare buying opportunity? Tune in as we break down whether this drop is a discount or a warning.
AST SpaceMobile just defied gravity, surging over 14% to a fresh all-time high after securing a prime spot on the U.S. Missile Defense Agency’s massive SHIELD program. With a contract ceiling of $151 billion, Wall Street is betting that ASTS is no longer just a cellular play—it’s a critical defense asset. In this episode of Implied, we break down how this "dual-use" validation changes the narrative, why investors are ignoring the dizzying 3,000x sales valuation, and whether AST can actually compete against titans like Lockheed Martin. Is this the start of a new era, or is the stock priced for perfection? Tune in to find out.
Ermenegildo Zegna stock has slid nearly 13% from last week’s highs after Bank of America downgraded the luxury house, slapping a sober $10 price target on the ticker. The core issue? Zegna is trading at a premium 22x earnings—rivaling industry titan LVMH—while its "cool" brand Thom Browne is shrinking and its pivot away from wholesale is dragging down cash flow. In this episode of Implied, we break down why the market is treating this "transition year" like a top-tier luxury play, and whether the "Made in Italy" label justifies the price tag while the engine is still being fixed.